Latest News

Real-world ADA 2026 data shows bempedoic acid add-on lowers major heart risks in type 2 diabetes more than ezetimibe, despite smaller LDL drops.

High-dose semaglutide shows improved kidney markers and lowers inflammation in obesity without diabetes, suggesting benefits beyond weight loss.

Both slow and fast transition periods were safe and effective, with minimal adverse events.

A pharmacist-led refill authorization program in endocrinology eliminated 3750 refill requests from provider in-baskets in 2025.

PET scans show long COVID mood and brain fog link to limbic activity, not widespread brain inflammation, reshaping COVID-19 treatment targets.

ADA data show CGM plus pharmacist groups helps seniors with type 2 diabetes prevent hypoglycemia, boost confidence, and prompt safer meds.

Elranatamab monotherapy produced a 92% overall response rate and a 45% complete response rate in patients with high-risk smoldering multiple myeloma, supporting the potential of BCMA-directed bispecific antibody therapy as an early intervention strategy before progression to active disease.

Cross-trial data from more than 6000 administrations show that a subcutaneous isatuximab on-body injector was highly reliable and well tolerated.

IDEAL trial data show iberdomide quadruplet therapy drives high response rates and rising MRD negativity in newly diagnosed multiple myeloma.

The policy direction is clear, but the regulatory mechanics are still working their way through the system.

The inaugural Joint MAD-ID/SIDP Annual Meeting was a celebration of learning and networking and focused on the educational needs of infectious diseases pharmacist specialists.

Darovasertib plus crizotinib boosts survival signals and response rates in HLA-A2–negative metastatic uveal melanoma, with manageable safety.

SERENA-6 shows early switch to oral SERD camizestrant plus CDK4/6 inhibitor improves PFS2, delays chemotherapy, and preserves quality of life.

The FDA granted Priority Review to the NDA for bezuclastinib plus sunitinib in previously treated advanced gastrointestinal stromal tumors (GIST).

Apnimed has submitted an NDA for AD109 for obstructive sleep apnea following positive phase 3 results from the SynAIRgy and LunAIRo trials.

A real-world study presented at ASCO 2026 found that early intravenous immunoglobulin administration within 4 weeks of starting talquetamab was associated with significantly lower infection rates and reduced 1-year mortality in patients with relapsed or refractory multiple myeloma.

Recent developments reflect a broader shift toward individualized, biologically informed care.

As retatrutide moves toward FDA submission, Jennifer Goldman, PharmD, breaks down the TRIUMPH-1 data—and what they mean for patient selection, dose escalation counseling, and positioning within the antiobesity pipeline.

Updated results from a phase 1 study showed that KLN-1010 produced reduced MRD-negative responses in all treated patients with RRMM.

The FDA approved the oral antiviral ensitrelvir (Xocova; Shionogi & Co, Ltd) for post-exposure prophylaxis (PEP) of COVID‑19 in adults and adolescents 12 years and older.